shortwave radio
shortwave radio with http://www.mdnewscast.net

shortwave radio

Medical Newscast

News for 01-Apr-25

Source: MedicineNet High Blood Pressure General
Sharp Drop in Blood Pressure After Rx May Be Risky for Some Heart Patients

Source: MedicineNet High Blood Pressure General
Stressed Childhood Might Raise Risk for High Blood Pressure Later

Source: MedicineNet High Blood Pressure General
High Blood Pressure Rates Have Doubled Worldwide Since 1975

Source: MedicineNet High Blood Pressure General
Study Finds Worrisome Heart Effects Among Some Football Players

Source: MedicineNet High Blood Pressure General
More Research Cites Salt's Potential Health Risks

Source: MedicineNet Diabetes General
Insulin Prices Skyrocket, Putting Many Diabetics in a Bind

Source: MedicineNet Diabetes General
Jardiance (empagliflozin)

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Source: MedicineNet Diabetes General
glipizide and metformin (Metaglip has been discontinued in the US)

Search the Web
shortwave radio
yahoo radio
radio 5 live
on radio
audio pro
audio cd cover
mojo radio
greek radio
audiobook
audio download

The Best shortwave radio website

All the shortwave radio information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best shortwave radio site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
shortwave radio.

shortwave radio

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Important privacy considerations when shopping for shortwave radio



The Internet is fast becoming the dominant medium for business and communication, but it still resembles something of a frontier, because there is little regulation. If you are looking for shortwave radio then you are doing so in an unregulated marketplace. Most efforts have relied on the Internet industry to police itself. Although there has been some notable success with self-policing, continued abuses have increased calls for government intervention. That's where our role in pre-checking shortwave radio sites comes in. Our shortwave radio provider is solid and reliable.

Some aspects of the Internet could undoubtedly use some regulation, but this task is not as simple as it may seem. The very nature of the Internet makes it difficult, if not impossible to regulate. However in the midst of this many shortwave radio retailers survive and prosper. At the same time, the absence of regulations means that everyone who uses this essentially public network can be a target for anyone who has the technical know-how and the will to invade their privacy. Privacy was foremost in our minds when sourcing the right shortwave radio retailer for you. Their link appears below.

While the threat from hackers is low for individuals, a more serious threat to personal privacy comes from unscrupulous shortwave radio companies that operate websites for quick quids. Many shortwave radio sites require you to register before you can use its services. Often you must provide personal information, such as your name, street address, and e-mail address. Then as you browse the site, data is collected as to which pages you visited, how long you remained on each page, the links you clicked, what terms you searched, and so on. After a number of visits to the site, a personal profile emerges. The question is, what do shortwave radio site operators do with this information?

Most claim that they use it to personalize your experience on the site. For instance, if a shortwave radio site learns that you are interested in shortwave radio, the next time you visit the site, you might be presented with an article or advertisements for that and related products. But some shortwave radio websites sell this information to marketers, which means that you may find yourself receiving unwanted catalogs from garden suppliers. Our preferred retailer does not do this.

We feel so confident that your shortwave radio shopping experience will be a good one that we have built this site so that you can go straight to the prime shortwave radio retailer without wasting a lot of time checking out vast numbers of very ordinary providers.

shortwave radio

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

If you are truly interested in the very best in shortwave radio then be sure you click the link above. We have researched the shortwave radio subject extensively and can guarantee that the people have the best.

The shortwave radio links on the right side of this page will take you directly to the specific item you need so look around. We have made it easy for you and of course this company stands behind their shortwave radio with total satisfaction guarantees.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
medical mailings | Fantasy Football Information | medical mailings | Go Antiques | Take It Correctly

Medical Newscast   Medical Meetings   MD News